Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | SCD | O00767 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2585147 | 0.82 | LMNA (0.40) | MAPTTP53KMT2ALMNASLC6A7 | |
| SCHEMBL2588200 | 0.81 | GAA (0.46) | MAPTTP53GAAKMT2ALMNA | |
| SCHEMBL2579158 | 0.80 | SLC6A7 (0.42) | MAPTTP53KMT2ALMNASLC6A7 | |
| Hydrochloric Acid SCHEMBL2588299 | 0.76 | ALDH1A1 (0.40) | MAPTTP53GAAKMT2ALMNA | |
| SCHEMBL2585530 | 0.75 | MEN1 (0.40) | MAPTTP53KMT2ALMNAMEN1 | |
| SCHEMBL3102323 | 0.71 | CYP3A4 (0.50) | MAPTTP53KMT2ALMNAALDH1A1 | |
| SCHEMBL2586737 | 0.70 | TP53 (0.55) | MAPTTP53LMNATHRB | |
| SCHEMBL3087962 | 0.69 | ALDH1A1 (0.39) | MAPTTP53GAALMNAALDH1A1 | |
| SCHEMBL2585782 | 0.68 | MAPT (0.48) | MAPTTP53KMT2ALMNAMEN1 | |
| SCHEMBL2581957 | 0.67 | GAA (0.46) | GAALMNAMEN1ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048879-B2 | Substituted 4,5,6,7-tetrahydro-isoxazolo[4,5-c]pyridine compounds and use thereof for producing medicaments | GRUENENTHAL GMBH (DE) | 2011-11-01 | — | — | US | claimed |
| US-20090076001-A1 | Substituted 4,5,6,7 -Tetrahydro-Isoxazolo[4,5-C]Pyridine Compounds and Use Thereof for Producing Medicaments | GRUENENTHAL GMBH (DE) | 2009-03-19 | — | — | US | claimed |
| EP-1869053-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-ISOXAZOLO[4,5-C]PYRIDINE COMPOUNDS AND THEIR USE IN THE PRODUCTION OF MEDICAMENTS | Grünenthal GmbH (DE) | 2007-12-26 | — | — | EP | claimed |
| WO-2006105945-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-ISOXAZOLO[4,5-C]PYRIDINE COMPOUNDS AND THEIR USE IN THE PRODUCTION OF MEDICAMENTS | Grünenthal GmbH (DE) | 2006-10-12 | — | — | WO | claimed |
| US-8048879-B2 | Substituted 4,5,6,7-tetrahydro-isoxazolo[4,5-c]pyridine compounds and use thereof for producing medicaments | GRUENENTHAL GMBH (DE) | 2011-11-01 | — | — | US | disclosed |
| US-20090076001-A1 | Substituted 4,5,6,7 -Tetrahydro-Isoxazolo[4,5-C]Pyridine Compounds and Use Thereof for Producing Medicaments | GRUENENTHAL GMBH (DE) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076001-A1 | Substituted 4,5,6,7 -Tetrahydro-Isoxazolo[4,5-C]Pyridine Compounds and Use Thereof for Producing Medicaments | P2RX5, P2RX4, P2RX7 | MAPT 3693/4885TP53 3916/4885GAA 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.